Sarepta Therapeutics, Inc. SRPT 深 沪
等待开盘 09-02 09:30:00 美东时间
21.33
+0.300
+1.43%
华盛通- 最 高21.82
- 今 开20.88
- 成交量 262.37万股
- 最 低 20.5451
- 昨 收 21.03
- 总市值 22.53亿
- 52周最高 25.32
- 市盈率 静 --
- 换手率 2.48%
- 52周最低 14.68
- 委 比 -88.57%
- 总股本 1.06亿
- 历史最高 181.83
- 量 比 0.72
- 振 幅 6.06%
- 历史最低 0.433
- 每 手 1
- 风险率 2.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings of $2.02 per share from the same period last year. The company reported quarterly sales of $401.300 m...
08-06 04:14
Sarepta taps Michael Severino as CEO
Sarepta Therapeutics (SRPT) has appointed Michael Severino as chief executive officer, effective July 28, 2026. Severino, the former CEO of Tessera Therapeutics, will also join Sarepta's board of dire...
07-27 20:40
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sarepta’s Boa...
07-27 20:37
Roche jumps despite reiterating 2026 outlook
Roche (RHHBY) (RHHBF) shares closed ~5% higher in Zurich on Thursday, recording its best single-day gain since November, even as the Swiss drugmaker reaffirmed its 2026 outlook with its financials for...
07-24 00:27
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target
Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
07-09 20:08
Sarepta Therapeutics宣布根据纳斯达克上市规则5635(c)(4)授予激励性股权
纳斯达克上市的罕见病精准基因疗法企业Sarepta Therapeutics（股票代码SRPT）于2026年6月30日，向2026年第二季度入职的30名新员工授...
07-01 04:30
分析师精选医疗健康板块个股：Palisade Bio（PALI）、Sarepta Therapeutics（SRPT）
两名医疗板块分析师先后对Palisade生物（PALI）与Sarepta医疗（SRPT）给出看涨评级。 关键评级与数据： 马克西姆集团分析师纳兹·拉赫曼重申...
06-30 22:58
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027
– Accepted for review with target action date of February 28, 2027 Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sN...
06-30 20:38
Sarepta Therapeutics 获FDA设定PDUFA目标审批日期为2027年2月28日
萨雷普塔疗法公司相关产品的美国食品药品监督管理局PDUFA目标审批日期已确定为2027年2月28日。 译文内容由第三方软件翻译。 声明：市场有风险，投资需谨慎...
06-30 20:37
